Endocrine Abstracts (2008) 16 P445

Long-term treatment with dopamine agonists is not associated with increased prevalence of valvular heart disease in patients with prolactinomas

Marleen Kars1, Victoria Delgado2, Eduard Holman2, Richard Feelders3, Jan Smit1, Hans Romijn1, Jeroen Bax2 & Alberto Pereira1


1Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, The Netherlands; 2Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; 3Section of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.


Objective: Treatment with ergot-derived dopamine agonists, pergolide and cabergoline, has been associated with an increased frequency of valvular heart disease in Parkinson’s disease. The aim of the present study was to assess the prevalence of valvular heart disease in patients treated with dopamine agonists for prolactinomas.

Design: Cross-sectional study.

Patients: We performed conventional two-dimensional and Doppler echocardiography in 78 consecutive patients with prolactinoma (mean age 47±1.4 years, 26% male, 33% macroprolactinoma) treated with dopamine agonists for at least 1 year (mean 8±0.6 years) and 78 control subjects (matched for age, gender, body surface, and left ventricular systolic function). Patients were classified according to treatment: patients treated with ergot-derived dopamine agonists (cabergoline, bromocriptine, and terguride) (group 1: n=57), and patients treated with non-ergot derived dopamine agonist (quinagolide) or other treatment modalities than dopamine agonists (group 2: n=21).

Results: Clinically relevant valvular heart disease was present in 12% (9 of 78) of patients vs. 17% (13 of 78) of controls (P=0.141), and in 14% (8 of 57) of patients treated with ergot-derived dopamine agonists vs. 5% (1 of 21) of patients treated with non-ergot derived dopamine agonists or no dopamine agonist (P=0.483). Mild regurgitation of the tricuspid valve was significantly more present in patients compared to controls (41% vs. 26%, P=0.042).

Conclusion: Long-term dopamine agonist therapy in patients with prolactinoma is not associated with increased prevalence of clinically relevant valvular heart disease.

Article tools

My recent searches

No recent searches.